EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Does Metabolic Manager Show Encouraging Outcomes in Alzheimer's?: Challenges and Opportunity for Protein Tyrosine Phosphatase 1b Inhibitors

Ritu Singh, Smita Jain, Vartika Paliwal, Kanika Verma, Sarvesh Paliwal iD, Swapnil Sharma iD

Drug Development Research · 2024

DOI: 10.1002/ddr.70026 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Development Research, 2024. Verfasst von Ritu Singh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Banasthali Vidyapith, Banasthali, Rajasthan, India. Hauptthemen laut MEDLINE: Alzheimer Disease, Protein Tyrosine Phosphatase, Non-Receptor Type 1, Enzyme Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 225 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Protein tyrosine phosphatase 1b (PTP1b) is a member of the protein tyrosine phosphatase (PTP) enzyme group and encoded as PTP1N gene. Studies have evidenced an overexpression of the PTP1b enzyme in metabolic syndrome, anxiety, schizophrenia, neurodegeneration, and neuroinflammation. PTP1b inhibitor negatively regulates insulin and leptin pathways and has been explored as an antidiabetic agent in various clinical trials. Notably, the preclinical studies have shown that recuperating metabolic dysfunction and dyshomeostasis can reverse cognition and could be a possible approach to mitigate multifaceted Alzheimer's disease (AD). PTP1b inhibitor thus has attracted attention in neuroscience, though the development is limited to the preclinical stage, and its exploration in large clinical trials is warranted. This review provides an insight on the development of PTP1b inhibitors from different sources in diabesity. The crosstalk between metabolic dysfunction and insulin insensitivity in AD and type‐2 diabetes has also been highlighted. Furthermore, this review presents the significance of PTP1b inhibition in AD based on pathophysiological facets, and recent evidences from preclinical and clinical studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseProtein Tyrosine Phosphatase, Non-Receptor Type 1Enzyme InhibitorsHumansAnimalsHypoglycemic AgentsDiabetes Mellitus, Type 2

Stichwörter der Autor:innen

metabolic syndromeneurodegenerationneuroinflammationoxidative stressprotein tyrosine phosphatase 1b enzyme

Substanzen

Protein Tyrosine Phosphatase, Non-Receptor Type 1Enzyme InhibitorsPTPN1 protein, humanHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Banasthali Vidyapith, Banasthali, Rajasthan, India.
  • Department of Internal Medicine, Division of Cardiology, LSU Health Sciences Center Shreveport, Louisiana, USA.

ORCID-Profile: Sarvesh Paliwal, Swapnil Sharma

Zitieren

APA

Singh, R., Jain, S., Paliwal, V., Verma, K., Paliwal, S., & Sharma, S. (2024). Does Metabolic Manager Show Encouraging Outcomes in Alzheimer's?: Challenges and Opportunity for Protein Tyrosine Phosphatase 1b Inhibitors. Drug Development Research. https://doi.org/10.1002/ddr.70026

Vancouver

Singh R, Jain S, Paliwal V, Verma K, Paliwal S, Sharma S. Does Metabolic Manager Show Encouraging Outcomes in Alzheimer's?: Challenges and Opportunity for Protein Tyrosine Phosphatase 1b Inhibitors. Drug Development Research. 2024. doi:10.1002/ddr.70026

BibTeX
@article{Singh2024,
  author = {Singh, Ritu and Jain, Smita and Paliwal, Vartika and Verma, Kanika and Paliwal, Sarvesh and Sharma, Swapnil},
  title = {Does Metabolic Manager Show Encouraging Outcomes in Alzheimer's?: Challenges and Opportunity for Protein Tyrosine Phosphatase 1b Inhibitors},
  journal = {Drug Development Research},
  year = {2024},
  doi = {10.1002/ddr.70026}
}
Kostenlos starten →